$AEMD $1.11?! at 52WKLOW BADLY oversold.. Average analysts price target is 600% higher from here at $6.50+! LOADING. Huge bounce coming. TINY FLOAT??????
H.C. Wainwright Keeps a Buy Rating on Aethlon Medical (AEMD)
Apr 20, 2022, 05:45 PM
H.C. Wainwright analyst reiterated a Buy rating on Aethlon Medical ( – ) today and set a price target of $9.00. The company’s shares closed last Wednesday at $1.23, close to its 52-week low of $1.12.
According to , Bernardino is a 5-star analyst with an average return of 24.9% and a 34.1% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Citius Pharmaceuticals.
Currently, the analyst consensus on Aethlon Medical is a Moderate Buy with an average price target of $6.50.
Aethlon Medical’s market cap is currently $19.88M and has a P/E ratio of -2.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which are most likely to make moves following their insider activities.
Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.
AI
